{"id":"placebo-like-asacol","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL4594475","moleculeType":"Protein"},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=placebo like asacol","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T05:50:56.541395+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T05:51:03.858520+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=placebo like asacol","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T05:51:04.533130+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4594475/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:51:05.194979+00:00"}},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a placebo, this product contains no active pharmaceutical ingredient and is intended to be indistinguishable from Asacol in appearance and administration. It is used in blinded clinical trials to control for placebo effects when evaluating the efficacy of mesalamine in inflammatory bowel disease. The placebo allows researchers to isolate the true therapeutic benefit of the active drug from psychological and expectation-based improvements.","oneSentence":"This is a placebo formulation designed to mimic Asacol (mesalamine) for use in clinical trials or comparative studies.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:01:05.336Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T05:51:07.032716+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"name":"Clinical trial control for inflammatory bowel disease (ulcerative colitis, Crohn's disease)"}]},"trialDetails":[{"nctId":"NCT02190526","phase":"PHASE4","title":"Effects of Mesalamine and Amitriptyline on Irritable Bowel Syndrome","status":"WITHDRAWN","sponsor":"Tehran University of Medical Sciences","startDate":"2014-09","conditions":"Diarrhea- Predominant Irritable Bowel Syndrome, Quality of Life","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL4594475"},"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"placebo like asacol","genericName":"placebo like asacol","companyName":"Tehran University of Medical Sciences","companyId":"tehran-university-of-medical-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo formulation designed to mimic Asacol (mesalamine) for use in clinical trials or comparative studies. Used for Clinical trial control for inflammatory bowel disease (ulcerative colitis, Crohn's disease).","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T05:51:07.032716+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}